Neuroprotective effects of acetylcholinesterase inhibitory peptides

Subscriber access provided by READING UNIV

Article

Neuroprotective effects of acetylcholinesterase inhibitory peptides from anchovy (Coilia mystus) against glutamate-induced toxicity in PC12 cells Tiantian Zhao, Guowan Su, Shuguang Wang, Qi Zhang, Jianan Zhang, Lin Zheng, Bao-Guo Sun, and Mouming Zhao J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.7b03945 • Publication Date (Web): 30 Nov 2017 Downloaded from http://pubs.acs.org on December 6, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 34

Journal of Agricultural and Food Chemistry

Neuroprotective effects of acetylcholinesterase inhibitory peptides from anchovy (Coilia mystus) against glutamate-induced toxicity in PC12 cells Tiantian Zhaoab, Guowan Suab, Shuguang Wangab, Qi Zhangab, Jianan Zhangab, Lin Zhengab, Baoguo Sunc, Mouming Zhaoabc* a

School of Food Science and Engineering, South China University of Technology, Guangzhou 510640, China b

Guangdong Food Green Processing and Nutrition Regulation Technologies Research Center, Guangzhou 510650, China

c

Beijing Advanced Innovation Center for Food Nutrition and Human Health，Beijing Technology & Business University (BTBU)，Beijing 100048,China.

Running title: Neuroprotective peptides from anchovy protein

Corresponding author Mouming Zhao Tel/Fax: +86 20 87113914 E-mail: [email protected]

1

ACS Paragon Plus Environment


1

Page 2 of 34

Abstract

2

Ameliorations of cholinergic system dysfunction and oxidative stress in

3

neurodegenerative diseases were main approaches to improve memory disorder. Our

4

previous investigation showed that anchovy protein hydrolysate (APH) could

5

attenuate

6

acetylcholinesterase (AChE) activity. Therefore, peptides with AChE inhibitory

7

activity in APH were explored and identified in this study, and their possible

8

neuroprotective mechanisms on glutamate induced apoptosis in PC12 were also

9

elucidated. Two peptides with strong AChE inhibitory capacity were identified as

10

Pro-Ala-Tyr-Cys-Ser (PAYCS) and Cys-Val-Gly-Ser-Tyr (CVGSY) by UPLC-MS/MS.

11

The AChE inhibitory was 23.68 ± 0.97% and 6.08 ± 0.41%, respectively. Treatment

12

with PAYCS and CVGSY could significantly (p < 0.05) increase cells viability, reduce

13

LDH release, ROS production, MDA content and the ratio of Bax/Bcl-2 of

14

glutamate-induced apoptosis PC 12 cells (82.78 ± 6.58 and 109.94 ± 7.16% of control,

15

respectively), as well as increase SOD and GSH-px activities. In addition, both the

16

peptides could inhibit Ca2+ influx but have no effects on MMP. Results indicated that

17

AChE inhibitory peptides (PAYCS and CVGSY) possibly protected the PC12 cells

18

against glutamate-induced apoptosis via inhibiting ROS production and Ca2+ influx.

19

PAYCS and CVGSY might be considered as nutraceuticals for alleviating memory

20

deficits.

21

Keywords Anchovy protein hydrolysates; Acetylcholinesterase; PC 12 cells;

22

Oxidative stress; Neuroprotection

scopolamine-induced

memory

deficits

2


in

mice

by

regulating

Page 3 of 34


23

Introduction

24

Memory degeneration and deficits are commonly found in age-related

25

Alzheimer’s (AD), Parkinson's disease and other neurodegenerative diseases.1-3 A

26

growing body of literature suggests that cholinergic system dysfunction is a hallmark

27

of memory deficits.4 As an important transmitter, acetylcholine (Ach) is responsible

28

for the electrical impulses conduction from cells to cells and could be rapidly

29

hydrolyzed by acetylcholinesterase (AChE).5 Therefore, enhancing cholinergic

30

transmission directly by inhibiting AChE has been targeted for alleviating memory

31

defects.6 For example, alpha-lipoic acid was proved to be very effective in increasing

32

the Ach release and decreasing the AChE activity in the hippocampus in bilateral

33

common carotid arteries occlusion-treated rats.7

34

In addition to cholinergic system dysfunction, apoptosis of neurons also plays a

35

vital role in the development of memory loss.8 Therefore, much effort has been done

36

to explore beneficial agents from natural sources to achieve neuroprotection. Si et al.

37

has reported that socampneoside II could ameliorate H2O2-induced oxidative stress

38

and apoptosis in PC12 cells which could be beneficial to neurodegenerative diseases.9

39

Additionally, green tea and its major polyphenol (-)-epigallocatechin-3-gallate

40

(EGCG),10 genistein,11 gallic acid,12 selenium polysaccharide,13 proanthocyanidin and

41

ellagitannin in berry fruits14 as well as other bioactive compounds were studied to be

42

neuroprotective which might be partly mediated via antioxidant effects. These

43

investigations on neuroprotective compounds indicated that the neuroprotective

44

compounds might be capable of modulating signaling pathways involved in oxidative

45

stress or inflammation, cell survival, neurotransmission, mitochondrial protection and

46

further enhancing memory even ameliorating neurodegenerative diseases.

47

Recently, the prevalence of memory-deficits-related diseases and lack of



48

effective pharmaceutical treatment have drawn an urgent need for novel therapeutic

49

methods. Bioactive peptides come from a wide range of sources. Some naturally exist

50

in the natural resources and some can be obtained from the hydrolysates of the animal

51

or plant proteins. These peptides play a key role in regulating the digestive, endocrine,

52

cardiovascular, immune, and nervous systems in human health.15 It is worthy to note

53

that peptides with antioxidant, anti-inflammatory or other bioactivities could also

54

exhibit neuroprotective capacity in nervous systems. An iron-chelating derivative of

55

peptide NAPVSIPQ could inhibit iron-catalyzed hydroxyl radical formation and

56

protect human neuroblastoma cell cultures against H2O2 toxicity.16 Hartwig et al.

57

found that Cerebrolysin had neuroprotective effects in CoCl2-induced cytotoxicity in

58

PC12 cells by decreasing production of superoxides and getting involved in GSK3β

59

pathway.17 Moreover, Chai et al. also obtained two bioactive peptides (Phe-Tyr-Tyr

60

and Asp-Trp) from Benthosema pterotum, which possessed cytoprotection effects on

61

both H2O2-induced apoptosis in SH-SY5Y cells and D-gal-induced memory deficit in

62

mice.18 Therefore, bioactive peptides might play a promising role in alleviating or

63

preventing memory deficits in the ageing and/or age-related neurodegenerative

64

diseases.

65

Our previous investigations showed that anchovy protein hydrolysate (APH)

66

exhibited antioxidative effect in vitro and memory-improving function in

67

scopolamine-induced memory impairment in mice.19 Moreover, further study showed

68

that APH exhibited significantly (p < 0.05) AChE inhibitory activity in brain tissue

69

homogenate of mice and could enhance memory in mice.19-20 However, the specific

70

peptide sequences with AChE inhibitory capacity in APH were still unknown.

71

Moreover, whether the AChE inhibitory peptides could be neuroprotective or not

72

needed to be explored.

ACS Paragon Plus 2 Environment

Page 4 of 34

Page 5 of 34


73

Glutamate is an important neurotransmitter in neurons and glial cells, and

74

strongly depends on calcium homeostasis and mitochondrial function.21 However,

75

excessive amounts of extracellular glutamate could induce cytotoxicity in neurons and

76

consequently lead to apoptosis.22 PC12 cells have been widely used for neurological

77

studies.23 Thus, the present study was carried out to identify AChE inhibitory peptides

78

in APH and further to determine whether the peptides displayed neuroprotective

79

effects against glutamate-induced cytotoxicity in PC 12 cells. Furthermore, the

80

possible underlying mechanisms were also elucidated.

81

Materials and methods

82

Chemicals

83

Anchovy was purchased from Huangsha aquatic product consumer market in

84

Guangzhou, China. Alcalase 2.4 L was purchased from Novozymes Biotechnology Co.

85

Ltd. (Beijing, China). Papain was purchased from Guangzhou Huaqi Biotechnology

86

Co. Ltd. (Guangzhou, China) and pancreatin was provided by Chongqing Xiangsheng

87

Biological Pharmaceutical Co., Ltd. (Chongqing, China). Cerebrolysin was purchased

88

from Cardinal Health Pharmacy (Guangzhou, China). Acetylthiocholine iodide

89

(ATCI), 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB), AChE from electric eel and

90

HEPES were purchased from Sigma Chemical Co. Ltd (St. Louis, MO, USA). The

91

PC12 cell line (rat pheochromocytoma cells) was purchased from the Cell Bank of the

92

Chinese Academy of Sciences (Shanghai, China). Lactate dehydrogenase (LDH)

93

release assay kit, reactive oxygen species (ROS) detection kit, malondialdehyde

94

(MDA) detection kit, glutathione peroxidase (GSH-px) detection kit, superoxide

95

dismutase (SOD) detection kit, mitochondrial membrane potential (MMP) detection

96

kit and Fura-2 AM were bought from Beyotime Institute of Biotechnology (Shanghai,

97

China). All the solvents for HPLC/UPLC were of HPLC grade. Other chemicals used



98

were of analytical grade.

99

Preparation of anchovy protein hydrolysate (APH)

100

APH was prepared as previously described.19 The anchovy meat mince was

101

hydrolyzed by a mixture of three proteases (Alcalase 2.4 L, papain and pancreatin) at

102

55 °C for 8 h and centrifuged at 5,000 ×g at 4 °C for 20 min. Then the supernatant

103

was collected, spray-dried. The inlet and outlet temperature of spray drying was 185

104

and 90 oC, respectively and the flow rate was 20 mL/min. The spray-dried powder

105

was stored at -20 °C until used. The protein content of APH was > 95%.

106

In vitro determination of AChE inhibition

107

The inhibitory effects of samples on AChE activity were measured according to

108

Ellman’s method24 and Rhee et al.25 with some modifications for peptides. HEPES

109

(pH 8.0, 50 mM) was chosen in the study. The 0.055 U/mL acetylcholinesterase and

110

7.5 mM ATCI were applied in this investigation. ATCI (30 µL), DTNB (125 µL),

111

HEPES (30 µL) and samples (50 µL, 10 mg/mL) were added in 96-well plate and then

112

incubated for 15 min at 37 oC, and then 30 µL AChE was added to activate the

113

reaction. The Varioskan Flash spectral scanning multimode reader (Thermo Fisher

114

Scientific, USA) was used to measure the absorbance at 412 nm after 15 min. In this

115

method, the absorbance of samples was recorded as Asample. The absorbance of

116

samples without AChE which was replaced by HEPES was recorded as Asample blank.

117

The absorbance of well without samples which was replaced by HEPES was recorded

118

as Acontrol. The absorbance of well without samples and AChE which were replaced by

119

HEPES was recorded as Acontrol blank. The AChE inhibitory rate was calculated as

120

follows:

121


Page 6 of 34

Page 7 of 34


122

Where Asample, Asample blank, Acontrol and Acontrol blank represent the absorbance of sample,

123

sample blank, control and control blank at 412 nm, respectively.

124

Purification of AChE inhibitory peptides from APH

125

To purify and identify the potential AChE inhibitory peptides in APH, Sephadex

126

G-25 gel filtration chromatography, RP-HPLC and UPLC-MS/MS were applied. The

127

APH sample was fractionated using Sephadex G-25 gel filtration chromatography

128

(2.6 × 70 cm) with an ultraviolet detector (STI-501Plus) at 220 nm and six major

129

peaks (Fr.1-6) were collected, pooled and vacuum-dried using a rotary evaporator

130

(RE-52A, Shanghai Yarong Biochemical Instrument Factory, Shanghai, China) for

131

the AChE inhibitory activity assessment. Then the fractions with stronger inhibitory

132

activity were pooled and further purified by Waters e2695 HPLC with a 2998 PDA

133

detector (Waters Corporation, USA) and a XBridgeTM Prep BEH130 C18 column

134

(10×150 mm, 5 µm, Waters). The elution program was set as 0-1 min, 5% acetonitrile

135

(B) and 95% trifluoroacetic acid (0.1%, v/v) in water (A); 1-35 min, 5-40% B; 35-36

136

min, 40% B; 36-40 min, 40-5% B; 40-42 min, 5% B at a flow rate of 1 mL/min. The

137

fractions were collected manually and lyophilized for the assay of AChE inhibitory

138

activity.

139

UPLC-MS/MS identification and sequence analysis

140

The resultant fraction that exhibited the strongest AChE inhibitory activity was

141

subjected to analytical RP-UPLC for further peptide analysis in an Agilent 1290

142

infinity machine using an SB-C18 column (2.1×50 mm, RRHD 1.8 µm, Agilent,

143

USA). Five microliters of each peptide sample (1 mg/mL) were loaded for each

144

elution. The flow rate was 0.50 mL/min. Methyl alcohol was used as the mobile phase

145

B while ultra-pure water was used as the mobile phase A. The elution program was

146

set as 0-5 min, 2% B; 5-10 min, 2-10% B; 10-15 min, 10-30% B; 15-20 min, 30-85%



147

B; 20-25 min, 85% B; 25.01-30 min, 2% B. Column temperature was 30 oC. The

148

elution peaks were detected at a wavelength of 220 nm. The identification of the

149

sequence and accurate molecular mass of peptides presented in Fr.4-6 was performed

150

by electrospray ionization- quadrupole time-of-flight micromass spectrometer

151

(ESI-Q-TOF-MS/MS). These data were obtained a Bruker maxis impact ultra-high

152

resolution mass spectrometer (Bruker Daltonics Inc., Billerica, MA). The mass range

153

was set at 80-1300 m/z in positive ion modes. The quadrupole ion energy was set at

154

4.0 eV while the collision inducing dissociation energy was set at 8.0 eV. The

155

parameters for the ESI interface were as follows: 180 oC drying gas temperature, 8.0

156

L/min drying gas flow and 1.5 bar ESI nebulizer pressure. Because of the little data of

157

anchovy sequence in UniProtKB, the computer program Data analysis, version 3.0

158

(Bruker Daltonics Inc., Billerica, MA) was applied to sequence the peptides by

159

manual de novo. Notably, the final resulted peptides molecular weight should match

160

the theory value (error ± 0.002 Da). The peptides were chemically synthesized by GL

161

Biochem Ltd. (Shanghai, China) and stored at -20 °C until use.

162

Cell culture and treatment

163

PC12 cells were cultured in RPMI 1640 medium supplemented with 10% (v/v)

164

fetal bovine serum at 37 oC in a humidified atmosphere of 5% carbon dioxide. Cells

165

were seeded in 96-well plates (1×105 cells/well). PAYCS and CVGSY derived from

166

anchovy protein hydrolysates were probably used as the health care products, and the

167

long-time use process was accompanied by glutamate or other impairment in the

168

nervous system. The PC12 cell model with adding samples and glutamate at the same

169

time (coincubation) was chosen to assess the protective effects of Cerebrolysin,

170

PAYCS and CVGSY on glutamate induced toxicity in PC12 cells.26 After being

171

cultured for 24 h, PC12 cells were treated with medium containing 0.5 mg/mL


Page 8 of 34

Page 9 of 34


172

Cerebrolysin (positive control), PAYCS and CVGSY and 32.5 mM glutamate for

173

another 24 h. In our pre-experiment, glutamate with 32.5 µM treatment for 24 h could

174

lead to 50-60% cell viability of PC12 cells. Therefore, 32.5 µM of the glutamate was

175

chosen as the test concentration. For these experiments, control and blank cultures

176

were also administered the same amount of PRIM 1640 (culture medium) and PBS,

177

respectively. The concentrations of peptides and Cerebrolysin in this experiment were

178

selected according to our preliminary experiment. All manipulations were repeated

179

three or more times under each treatment condition.

180

Cell viability assay

181

After 24 h of incubation, 100 µL of MTT (0.5 mg/mL) was added to each well

182

with additional incubation at 37 °C for 4 h, and the formazan crystals were dissolved

183

in DMSO (150 µL). Absorbance of the formazan solution was measured at 570 nm

184

with a microplate reader (Thermo Fisher Scientific, USA). Cell survival was

185

expressed as a relative percentage of the untreated control. The toxicity of samples

186

and the selection of glutamate concentration were both conducted by this method.

187

Lactate dehydrogenase (LDH) release assay

188

LDH can be released from cells with damaged membranes, thus the LDH level in

189

the culture supernatant is a reflection of cellular injury extent. At the end of treatments,

190

the supernatant was collected and LDH leakage was measured using the assay kit

191

according to the manufacturer’s instructions and the absorbance was measured at a

192

wavelength of 450 nm using a microplate reader (Thermo Fisher Scientific, USA).

193

Morphological analysis

194

To observe nuclear changes that occurred during apoptosis, the chromatin

195

specific dye, Hoechst 33258, was used according to Ma et al.27 Briefly, PC12 cells



196

were harvested and washed with PBS for 3 times. Then they were fixed by 4%

197

paraformaldehyde for 20 min at room temperature. After that, the fixed PC12 cells

198

were washed with PBS for 3 times before they were exposed to 5 µg/mL Hoechst

199

33258 for 15 min at room temperature in the dark. The samples were washed and

200

observed under a confocal laser scanning microscope (Leica TCS-SP5, Germany) at

201

100× magnification.

202

Determination of SOD, GSH-px and MDA levels

203

After the cell treatment, the medium was removed and the cells were washed

204

thrice with PBS. Cells were collected, centrifuged, and re-suspended in PBS (200 µL),

205

dissociated

206

(radio-immunoprecipitation assay) lysis and 1mM PMSF (phenylmethanesulfonyl

207

fluoride), and centrifuged for 6 min (13,000 ×g). The supernatant was used to

208

measure the GSH-Px, SOD and MDA activities using assay kit based on the specified

209

manufacturer’s instructions.

210

Measurement of intracellular ROS

by cell lysis

buffer which was consist of 200 µL RIPA

211

Intracellular ROS was monitored by using the DCFH-DA (2,7-Dichlorodi

212

-hydrofluorescein diacetate) fluorescent probe according to the ROS assay kit. At the

213

end of treatment, cells were incubated with 10 µM DCFH-DA at 37 oC for 30 min,

214

and then washed twice with PBS. DCFH could be oxidized to be the strong green

215

fluorescent material-dichlorofluorescein (DCF) at the presence of ROS. The intensity

216

of fluorescent (Ex=854 nm, Em=525 nm) was measured using a microplate reader

217

(Thermo Fisher Scientific, USA).

218

Measurement of intracellular calcium concentration of ([Ca2+]i)

219

The concentration of [Ca2+]i was measured with Fluo-2/AM. At the end of


Page 10 of 34

Page 11 of 34


220

treatment, the PC12 cells were collected by tripsin digestion and then incubated with

221

Fluo-2/AM (final concentration 5 µM) for 30 min at 37 oC, and then the fluid of PC

222

12 cells was washed and plated on 96-well assay plates. Additionally, the maximum

223

fluorescence ratio (Rmax) was conducted by adding Triton 100 (0.1%) into the cells to

224

saturate Fura-2 and Ca2+ and then measured the value at 340 and 380 nm to get the

225

ratio (F340/F380). The minimum fluorescence ratio (Rmin) was conducted by adding a

226

high concentration of Ca2+ chelating agent (EGTA, ethylene glycol bis (2-aminoethyl

227

ether) tetraacetic acid, final concentration at 5mM, pH 8.5) into the cells to fully

228

chelate Ca2+ and then measured the value at 340 and 380 nm to get the ratio (F340/F380).

229

Changes of [Ca2+]i were measured using a microplate reader. [Ca2+]i was calculated as

230

follows: ሾCaଶା ሿ௜ = K ௗ ×

ܴ − ܴ௠௜௡ ‫ܨ‬௠௜௡ × ܴ௠௔௫ − ܴ ‫ܨ‬௠௔௫

231 232

Where Kd (224 nM) represents the dissociation constant of the reaction between

233

Fura-2 and Ca2+. The Rmax and Rmin were determined according to the method

234

mentioned above. The Fmin and Fmax was the Fura-2 fluorescence intensity (F380)

235

measured at 380 nm excitation wavelength when Ca2+ was zero and saturated,

236

respectively.

237

Measurement of MMP (∆Ψm)

238

When

∆Ψm

is

high,

239

5,5’,6,6’-tetrachloro-1,10,3,30-tetraethylbenzimidazol-carbocyanine

240

could be gathered in the mitochondrial matrix leading to the formation of polymer

241

(J-aggregates) which can produce red fluorescence. While when ∆Ψm is low, JC-1

242

could not be gathered in the mitochondrial matrix resulting in the JC-1 monomer

243

(monomer) which can produce green fluorescence. Therefore, it can be used as a


iodide

(JC-1)


244

sensitive measure of changes in mitochondrial membrane potential.28 The detection

245

was conducted according to the assay kit. Briefly, at the end of treatment, cells were

246

incubated with JC-1 (working solution) for 30 min at 37 oC, and then were

247

centrifuged for 4 min at 600 ×g. Cell sample was collected and washed twice with

248

PBS followed by re-floating and analyzing with a Thermo Scientific Lumina

249

fluorescence spectrophotometer (Thermo Fisher Scientific Co., USA) The ratio of

250

monomer and aggerate fluorescence intensity was calculated for the ∆Ψm change.

251

Western blotting

252

To analyze the Bax and Bcl-2 protein expression, the cytosolic fractions were

253

prepared by cell lysis. The protein concentration was determined using the BCA

254

method, after which equal amounts of protein (25 µg) were electrophoresed.

255

Following electrophoresis, the proteins were transferred from the gel to a PVDF

256

membrane using an electric transfer system. Non-specific binding was blocked with 5%

257

skim milk in Tris buffered saline with Tween (TBST) buffer (5 mM Tris-HCl, pH 7.6,

258

136 mM NaCl and 0.1% Tween-20) for 1.5 h. The blots were incubated with

259

antibodies against Bcl-2 (1:500), Bax (1:500) and actin (1:1000) overnight at 4 oC,

260

after which they were washed 3 times with 1 × TBST. The blots were incubated for 1

261

h at room temperature with a 1:1000 dilution of horseradish peroxidase-labeled

262

anti-rabbit or anti-mouse IgG. Then the blots were washed 3 times with 1× TBST

263

before they were developed using an Azure c300 Chemiluminescent Western Blot

264

Imaging System™ (Azure Biosystems, Inc., Dublin, CA, USA).

265

Statistical analysis

266

Statistical analysis was performed using the statistical package SPSS 17.0 (SPSS

267

Inc., Chicago, IL) with ANOVA analysis. Duncan post-hoc test was employed for


Page 12 of 34

Page 13 of 34


268

comparison of mean values among treatments and for assessment of significant

269

differences (p < 0.05) among treatments. Data were expressed as “means ± standard

270

deviation” of triplicate determinations.

271

Results

272

Purification and identification of peptides from APH

273

Cerebrolysin, as a peptidergic drug used clinically in dementia, was chosen as

274

the positive control in this study.17 APH was initially separated into six fractions

275

(Fr.1-Fr.6) by gel filtration chromatography (Fig. 1A). The AChE inhibitory capacities

276

of Fr.1-Fr.6 are presented in Fig. 1B. Fr.4 showed the highest AChE inhibitory rate

277

(12.06 ± 0.36% at 10 mg/mL). Then Fr.4 was further separated into ten fractions (Fig.

278

1C) and their AChE inhibitory capacities are showed in Fig 1D, Fr.4-6 exhibited the

279

strongest AChE inhibitory capacity (23.30 ± 0.97% at 10 mg/mL) among all the

280

fractions. Therefore, Fr.4-6 was collected and further analyzed by UPLC-MS/MS.

281

Among twelve peptides which were identified, two AChE inhibitory peptides, PAYCS

282

(m/z 540.1936 Da) and CVGSY (m/z 527.1955 Da), were investigated (Fig.1E/F).

283

They exhibited AChE inhibitory capacity with 23.68 ± 0.97% and 6.08 ± 0.41%

284

(Fig.1G), respectively.

285

Effects of PAYCS and CVGSY on cell cytotoxicity

286

According to our previous pre-experiment, 32.5 mM glutamate could lead to

287

40-50% cell death and 0.5 mg/mL sample could be better for neuroprotection without

288

cytoxicity. Therefore, the proper parameters were applied in this study. MTT results

289

showed that all the peptides did not show cytotoxicity in PC12 cells (Fig.2A).

290

Additionally, the viability of cells exposed to 32.5 mM glutamate for 24 h was 49.38

291

± 2.34% of the control value. Fig. 2B presents that glutamate-induced cell viability



292

reduction in PC12 cells was attenuated by treatment with Cerebrolysin, PAYCS or

293

CVGSY. The cell viability of Cerebrolysin, PAYCS or CVGSY treated groups was

294

raised to 60.38 ± 1.69%, 64.19 ± 3.19% and 65.08 ± 2.44% of the control value,

295

respectively.

296

Effects of PAYCS and CVGSY on LDH release

297

LDH release is considered as an indicator of cellular impairment. Treatment with

298

glutamate resulted in increasing LDH release into the medium, which was 569.52 ±

299

33.26% of the control group (Fig. 2C). Interestingly, treatment of PC12 cells with

300

Cerebrolysin, PAYCS or CVGSY at 0.5 mg/mL significantly (p < 0.05) suppressed

301

LDH leakage. Moreover, CVGSY showed the highest inhibition effect, followed by

302

Cerebrolysin and PAYCS.

303

Effects of PAYCS and CVGSY on the morphology of cell nuclei

304

The protective effects of PAYCS and CVGSY on glutamate-induced cytotoxicity

305

in PC12 cells were also confirmed by morphological observations. Under inverted

306

light microscope, glutamate caused marked morphological changes (nuclear

307

condensation, membrane blebbing, nuclear fragmentation and apoptotic bodies) in

308

PC12 cells, while Cerebrolysin, PAYCS or CVGSY at 0.5 mg/mL mitigated such

309

morphological features (Fig. 3).

310

Effects of PAYCS and CVGSY on intracellular ROS，MDA contents, SOD activity

311

and GSH-px activities

312

As shown in Fig. 4A, the intracellular ROS generation in glutamate treated group

313

was 3.42 times higher than that of the control group. PAYCS and CVGSY (0.5

314

mg/mL) could significantly reduce ROS production to 266.12 ± 5.21% and 282.83 ±

315

2.71%, respectively (p < 0.05). However, Cerebrolysin only showed slight inhibitory


Page 14 of 34

Page 15 of 34


316

capacity (324.28 ± 3.68%).

317

Cell death caused by ROS overproduction is accompanied by a lipid peroxide

318

increment and activity of enzymes changes. As shown in Fig. 4 B, C and D, after

319

PC12 cells were exposed to glutamate, the decreased activities of SOD and GSH-px

320

and elevated contents of MDA were observed. Treatment of PC12 cells with

321

Cerebrolysin, PAYCS or CVGSY (0.5 mg/mL) caused a marked increase in the SOD

322

activity from 59.95 ± 2.86 U/mg prot in glutamate treated cells to 70.49 ± 0.39, 73.98

323

± 0.32 and 75.01± 0.92 U/mg prot, respectively (Fig. 4 B). Likewise, GSH-Px were

324

significantly up-regulated in all treated cell groups compared with the glutamate

325

treated group (Fig. 4 C). Furthermore, treatment with Cerebrolysin, PAYCS and

326

CVGSY significantly decreased the up-regulated levels of MDA (Fig. 4 D).

327

Effects of PAYCS and CVGSY on intracellular Ca2+ concentration

328

It was reported that glutamate toxicity involves peroxide production, which

329

contributes to loss of Ca2+ homeostasis.29 As shown in Fig. 5A, exposure to glutamate

330

for 24 h resulted in an obvious increase of fluorescence intensity of [Ca2+]i (1003.32 ±

331

115.36 nM). While in glutamate treated PC 12 cells, it was markedly down-regulated

332

by Cerebrolysin, PAYCS or CVGSY (0.5 mg/mL) treatment, which was 13.69 ± 4.16,

333

5.69 ± 4.16 1.95 and 5.02 ± 1.52 nM, respectively.

334

Effects of PAYCS and CVGSY on MMP (∆Ψm)

335

MMP collapse has been implicated in several models of apoptosis. To examine

336

glutamate-induced apoptosis and the effect of PAYCS and CVGSY on apoptosis,

337

MMP was measured using JC-1 staining method.27 The results revealed that MMP

338

was partly lost when PC12 cells were exposed to glutamate. However, the ratio of

339

aggerates and monomer was not significantly rescued by treatment with Cerebrolysin,



Page 16 of 34

340

PAYCS or CVGSY for 24 h in glutamate injured PC12 cells (Fig. 5 B).

341

Effects of PAYCS and CVGSY on the protein expression of Bcl-2 and Bax

342

The inhibitory effect of PAYCS and CVGSY on glutamate-induced apoptosis

343

was assessed by measuring changes in the levels of apoptosis-related protein

344

expressions using western blotting method. As shown in Fig.6, Bax upregulation and

345

Bcl-2 down-regulation expression was observed in the glutamate treated group as

346

compared with control group. PAYCS and CVGSY treatment significantly reversed

347

the Bax and Bcl-2 expression levels (p < 0.05). While, Cerebrolysin could not

348

significantly up-regulate the expression of Bcl-2 (p > 0.05). The Bax/Bcl-2 ratio after

349

glutamate treatment was 1.6-fold higher than that of the control group. Treatment with

350

Cerebrolysin, PAYCS or CVGSY altered the Bax/Bcl-2 ratio to 77.67 ± 4.08%，82.78

351

± 6.58% ， 109.94 ± 7.16%, when compared with that of the control group,

352

respectively.

353

Discussion

354

Recently, the existence of peptides with biological activities derived from foods

355

has attracted a lot of attention for showing beneficial effects for health. Marine

356

fish-derived bioactive peptides might be involved in various biological functions (e.g.,

357

angiotensin-I-converting

358

antimicrobial, anticoagulant and matrix metalloproteinases-1 inhibition activities)

359

based on their structural properties, amino acid composition, sequences, and nutrient

360

utilization.30-31 In our previous study, hydrolysates derived from Anchovy protein

361

were proved to be capable of regulating the mRNA expression of choline

362

acetyltransferase and AChE activity to combat memory-impairment in mice.19

363

Therefore, APH was chosen for the further purification of potential AChE inhibitory

enzyme

inhibition,

antioxidant,


immunomodulatory,

Page 17 of 34


364

peptides in the hydrolysates. Cerebrolysin displays neurotrophic activity and could

365

protect primary neurons from glutamate-induced excitotoxicity.17 Thus, Cerebrolysin

366

was chosen as the positive control in this study. AChE inhibitory results showed that

367

PAYCS exhibited higher AChE inhibitory capacity than CVGSY and Cerebrolysin.

368

This might be related to the different amino acid compositions and sequence in

369

peptides.

370

Further, we aimed to investigate the possible protective effects of PAYCS and

371

CVGSY on the glutamate-induced toxicity in cultured PC12 cells and elucidate the

372

underlying mechanism. Glutamate is a neurotransmitter mediating excitatory synaptic

373

responses. However, excessive content of extracellular glutamate is related to the

374

neuronal disorders.32 It is worthy to note that oxidative stress and glutamate

375

receptor-mediated neurotoxicity are two main mechanisms involved with glutamate

376

neurotoxicity.29 The oxidative stress related to glutamate neurotoxicity is mediated by

377

ROS production, mitochondrial dysfunction and several apoptosis-related deaths

378

signaling pathways.33 Because glutamate receptor-mediated cytotoxicity is related to

379

the activation of glutamate receptors (NMDA receptors), it leads to the massive influx

380

of Ca2+ and cell death.27 The neuroprotective effects of PAYCS and CVGSY on

381

glutamate-induced cytotoxicity in PC12 cells were investigated next.

382

Sample toxicity results demonstrated that PAYCS and CVGSY (0.5 mg/mL) did

383

not affect the viability of PC12 cells (Fig. 2A), and the decreased cell viability

384

resulted from glutamate treatment was significantly attenuated by PAYCS and

385

CVGSY treatment (Fig. 2B). Additionally, the leakage of LDH in culture medium

386

was detected after being exposed to glutamate, indicating that cell membrane integrity

387

was destroyed, which could also be ameliorated by treatment with PAYCS and

388

CVGSY (Fig. 2C). Also, Cerebrolysin, as a positive control could reverse the damage



389

induced by glutamate. CVGSY showed better LDH leakage alleviation than that of

390

Cerebrolysin and PAYCS. Similarly, Boshra and Atwa had investigated reversed

391

effect of Cerebrolysin on LDH leakage in the ischemic myocardial tissue.34

392

Additionally, another cell apoptosis indicator was the morphological of nuclear

393

chromatins which was investigated. When PC12 cells were exposed to glutamate, the

394

morphological features of nuclear chromatins were obviously observed after staining.

395

The nuclear condensation, membrane blebbing, nuclear fragmentation and apoptotic

396

bodies were observed. These changes could be partially reversed by PAYCS and

397

CVGSY as well as Cerebrolysin treatment (Fig. 3).

398

One of the main features of neuronal damage, in particular of glutamate-induced

399

cells toxicity is the production of ROS.21 The accumulation of ROS was related to the

400

cell death which could result in oxidative injury through lipid peroxidation, protein

401

deficit, DNA damage and mitochondrial dysfunction.35 Additionally, multiple reports

402

have proved that antioxidants could alleviate or delay oxidative stress induced

403

apoptosis in cells.36-37 Such antioxidants are reported to reverse oxidative stress by

404

upregulating the endogenous antioxidant defense systems levels like glutathione

405

peroxidase. Results (Fig. 4A) showed that glutamate treatment significantly induced

406

ROS accumulation in cells, while cells treated with PAYCS and CVGSY exihibited a

407

significant reduction of ROS production compared with the glutamate treated cells (p

408

< 0.05). This effect could be partly due to the free radicals quenching ability of Tyr

409

and Cys in PAYCS and CVGSY. The hydrogen donors of the reactivity phenolic

410

structure in Tyr and sulydryl group in Cys could be responsible for their free radical

411

scavenging capacity in damaged PC12 cells.38-39 Apart from ROS accumulation,

412

glutamate treatment could also induce a significant decrease in the activities of SOD

413

and GSH-px, as well as a significant increase in the level of MDA in PC12 cells.


Page 18 of 34

Page 19 of 34


414

These parameters could be reversed by the treatment of PAYCS and CVGSY, which

415

indicated that PAYCS and CVGSY acted as antioxidants to protect PC12 cells against

416

oxidative damage. Furthermore, PAYCS showed better inhibitory effects on

417

intracellular ROS content and MDA content, as well as better up-regulation functions

418

on SOD and GSH-px activities than CVGSY and Cerebrolysin.

419

Previous studies reported that glutamate can result in an increase of the

420

cytoplasmic Ca2+ concentration which is caused by ROS formation. Furthermore,

421

Ca2+ accumulation could induce ROS generation.40-41 Additionally, mitochondria, as a

422

very effective Ca2+ buffer, could intake massive amounts of cytosolic Ca2+ at the

423

expense of MMP, resulting in MMP loss.28 Moreover, the disruption of MMP causes

424

apoptosis-related factors released which leads to nuclear condensation, and generates

425

secondary ROS, eventually results in apoptosis.27,42 In this study, glutamate led to

426

Ca2+ influx and MMP loss, while PAYCS and CVGSY treatment significantly

427

prevented the influx of Ca2+ (p < 0.05), whereas the MMP disruption was not

428

significantly ameliarated by PAYCS, CVGSY and Cerebrolysin treatment. The

429

injuries appeared in neuronal cells might be predominantly induced by excessive

430

influx of calcium into neurons through ionic channels triggered which was activated

431

by the glutamate receptors.43 Additionally, calcium overload resulted in proteolytic

432

enzymes over stimulation, lipid peroxidation, free-radical formation and other injuries

433

in cells.44-46 The obtained results showed that PAYCS and CVGSY could significantly

434

decrease the elevated level of intracellular Ca2+ and decrease the overproduction of

435

MDA levels (which was related to the lipid peroxidation and oxidative stress) induced

436

by glutamate in neuronal cells (p < 0.05). The inhibition of lipid peroxidation and

437

oxidative stress might be an explanation for the inhibitory effects of PAYCS and

438

CVGSY on Ca2+ influx and the neuroprotection effects on glutamate induced toxicity



439

in PC12 cells. However, whether the reductions in intracellular Ca2+ which were

440

observed by the treatment with PAYCS and CVGSY involved with the NMDA

441

receptor remains to be determined.

442

Mitochondrial dysfunctions, glutamate excitotoxicity and sequential apoptosis

443

are tightly in relation to the pathogenesis of neurodegenerative disease like AD.21 The

444

Bcl-2 family members (pro- and anti-apoptotic) are the key regulators of the

445

mitochondrial related apoptosis.47 Therefore, the ratio of pro and anti-apoptotic

446

members was crutial to predict the apoptotic fate of the cell.48 Our results indicated

447

that glutamate significantly up- and down-regulated the expression of Bax and Bcl-2

448

proteins in PC12 cells, respectively (Fig.6). Reversal of these trends by PAYCS and

449

CVGSY treatment were found. Thus, we could conclude that PAYCS and CVGSY

450

protected PC12 cells from glutamate-induced apoptosis, which may be through the

451

inhibition of mitochondrial apoptotic pathway.

452

In summary, two AChE inhibitory pentapeptides, sequenced as PAYCS and

453

CVGSY were identified from APH. The subsequent study demonstrated that PAYCS

454

and CVGSY exhibited neuroprotective effects on glutamate-induced toxicity in PC12

455

cells through inhibiting ROS production and Ca2+ influx. The different protective

456

effects of PAYCS and CVGSY might be partly related to the differences in the amino

457

acid compositions and sequences. The AChE inhibitory peptides, PAYCS and

458

CVGSY may be potential neuroprotective compounds for protecting against apoptosis

459

induced by glutamate cytotoxicity. Further study is needed to elucidate its apoptosis

460

cascade signaling and the underlying molecular mechanisms as well as the absorption

461

and transport mechanisms.

462

Conflicts of interest


Page 20 of 34

Page 21 of 34


463

The authors declare that there are no conflicts of interest.

464

Acknowledgements

465

The authors gratefully acknowledge the Strategic Emerging Industry Key

466

Scientific and Technological Program of Guangdong Province (No. 2012A020800002

467

and No. 2012A080800014), the Science and Technology Program of Guangzhou,

468

China (2012Y2-00012) and State Key Research and Development Plans (Project No.

469

2017YFD0400200 and 2017YFD0400100) for their financial supports.

470 471

References

472

(1) Lee, J. K.; Jin, H. K.; Endo, S.; Schuchman, E. H.; Carter, J. E.; Bae, J. s., Intracerebral

473

transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and

474

rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. Stem cells

475

2010, 28, 329-343.

476

(2) Jacobs, D. M.; Marder, K.; Côté, L. J.; Sano, M.; Stern, Y.; Mayeux, R., Neuropsychological

477

characteristics of preclinical dementia in Parkinson's disease. Neurology 1995, 45, 1691-1696.

478

(3) Meyer, U.; Knuesel, I.; Nyffeler, M.; Feldon, J., Chronic clozapine treatment improves prenatal

479

infection-induced working memory deficits without influencing adult hippocampal neurogenesis.

480

Psychopharmacology 2010, 208, 531-543.

481

(4) Haider, S.; Saleem, S.; Perveen, T.; Tabassum, S.; Batool, Z.; Sadir, S.; Liaquat, L.; Madiha, S.,

482

Age-related learning and memory deficits in rats: role of altered brain neurotransmitters,

483

acetylcholinesterase activity and changes in antioxidant defense system. Age 2014, 36, 9653.

484

(5) Ladner, C. J.; Lee, J. M., Pharmacological drug treatment of Alzheimer disease: the cholinergic

485

hypothesis revisited. J. Neuropath. Exp. Neur. 1998, 57, 719-731.

486

(6) Preet, A.; Baldev, S., A review on cholinesterase inhibitors for Alzheimer's disease. Arch. Pharm.

487

Res. 2013, 36, 375-399.

488

(7) Zhao, R.R.; Xu, F.; Xu, X.C.; Tan, G.J.; Liu, L.M.; Wu, N.; Zhang, W.Z.; Liu, J.X., Effects of

489

alpha-lipoic acid on spatial learning and memory, oxidative stress, and central cholinergic system in a

490

rat model of vascular dementia. Neurosci. Lett. 2015, 587, 113-119.



491

(8) Rosello, A.; Warnes, G.; Meier, U. C., Cell death pathways and autophagy in the central nervous

492

system and its involvement in neurodegeneration, immunity and central nervous system infection: to

493

die or not to die--that is the question. Clin. Exp. Immunol. 2012, 168, 52-57.

494

(9) Si, C. L.; Shen, T.; Jiang, Y. Y.; Wu, L.; Yu, G. J.; Ren, X. D.; Xu, G. H.; Hu, W. C., Antioxidant

495

properties and neuroprotective effects of isocampneoside II on hydrogen peroxide-induced oxidative

496

injury in PC12 cells. Food Chem. Toxicol. 2013, 59, 145-152.

497

(10) Mandel, S.; Weinreb, O.; Amit, T.; Youdim, M. B., Cell signaling pathways in the neuroprotective

498

actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative

499

diseases. J. Neurochem. 2004, 88, 1555-1569.

500

(11) Ma, W. W.; Yuan, L. H.; Yu, H. L.; Ding, B. J.; Xi, Y. D.; Feng, J. F.; Xiao, R., Genistein as a

501

neuroprotective antioxidant attenuates redox imbalance induced by β-amyloid peptides 25-35 in PC12

502

cells. Int. J. Dev. Neurosci. 2010, 28, 289-295.

503

(12) Mansouri, M. T.; Farbood, Y.; Sameri, M. J.; Sarkaki, A.; Naghizadeh, B.; Rafeirad, M.,

504

Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in

505

rats. Food Chem. 2013, 138, 1028-1033.

506

(13) Wei, D.; Chen, T.; Yan, M.; Zhao, W.; Li, F.; Cheng, W.; Yuan, L., Synthesis, characterization,

507

antioxidant activity and neuroprotective effects of selenium polysaccharide from Radix hedysari.

508

Carbohyd. Polym. 2015, 125, 161-168.

509

(14) Shukitt-Hale, B.; Carey, A. N.; Jenkins, D.; Rabin, B. M.; Joseph, J. A., Beneficial effects of fruit

510

extracts on neuronal function and behavior in a rodent model of accelerated aging. Neurobiol. Aging

511

2007, 28, 1187-1194.

512

(15) Sánchez, A.; Vázquez, A., Bioactive peptides: A review. Food Qual. Saf. 2017, 1, 29-46.

513

(16) Dan, B.; Weiner, L.; Youdim, M. B. H.; Fridkin, M., A Novel Iron-Chelating Derivative of the

514

Neuroprotective Peptide NAPVSIPQ Shows Superior Antioxidant and Antineurodegenerative

515

Capabilities. J. Med. Chem. 2008, 51, 126-134.

516

(17) Kerstin, H.; Viktoria, F.; Heidi, J. B.; Stefan, W.; Tanja, F.; Sebastien, C. D.; Dieter, M.; Herbert,

517

M.; Ludwig, A., Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3β

518

signaling. Int. J. Dev. Neurosci. 2014, 38, 52-58.

519

(18) Chai, H. J.; Wu, C. J.; Yang, S. H.; Li, T. L.; Pan, B. S., Peptides from hydrolysate of lantern fish

520

(Benthosema pterotum) proved neuroprotective in vitro and in vivo. J. Funct. Foods 2016, 24,


Page 22 of 34

Page 23 of 34


521

438-449.

522

(19) Su, G.; Zhao, T.; Zhao, Y.; Sun-Waterhouse, D.; Qiu, C.; Huang, P.; Zhao, M., Effect of anchovy

523

(Coilia

524

memory-impairment in mice. Food Res. Int. 2016, 82, 112-120.

525

(20) Zhao, T.; Xu, J.; Zhao, H.; Jiang, W.; Guo, X.; Zhao, M.; Sun-Waterhouse, D.; Zhao, Q.; Su, G.,

526

Antioxidant and anti-acetylcholinesterase activities of anchovy (Coilia mystus) protein hydrolysates

527

and their memory-improving effects on scopolamine-induced amnesia mice. Int. J. Food Sci. Tech.

528

2017, 52, 504-510.

529

(21) Cassano, T.; Pace, L.; Bedse, G.; Lavecchia, A. M.; De, M. F.; Gaetani, S.; Serviddio, G.,

530

Glutamate

531

Neurodegeneration. Curr. Alzheimer Res. 2016, 13, 185-197.

532

(22) Tan, J. W.; Tham, C. L.; Israf, D. A.; Sang, H. L.; Min, K. K., Neuroprotective effects of biochanin

533

A against glutamate-induced cytotoxicity in PC12 cells via apoptosis inhibition. Neurochem. Res. 2013,

534

38, 512-518.

535

(23) Penugonda, S.; Mare, S.; Goldstein, G.; Banks, W. A.; Ercal, N., Effects of N-acetylcysteine amide

536

(NACA), a novel thiol antioxidant against glutamate-induced cytotoxicity in neuronal cell line PC12.

537

Brain Res. 2005, 1056, 132-138.

538

(24) Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M., A new and rapid colorimetric

539

determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.

540

(25) Rhee, I. K.; Meent, M. V. D.; Ingkaninan, K.; Verpoorte, R., Screening for acetylcholinesterase

541

inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with

542

bioactivity staining. J. Chromatogr. A 2001, 915, 217-223.

543

(26) Sasaki, N.; Toda, T.; Kaneko, T.; Baba, N.; Matsuo, M., Protective effects of flavonoids on the

544

cytotoxicity of linoleic acid hydroperoxide toward rat pheochromocytoma PC12 cells. Chem.Biol.

545

Interact. 2003, 145, 101-116.

546

(27) Ma, S.; Liu, H.; Jiao, H.; Wang, L.; Chen, L.; Liang, J.; Zhao, M.; Zhang, X., Neuroprotective

547

effect of ginkgolide K on glutamate-induced cytotoxicity in PC 12 cells via inhibition of ROS

548

generation and Ca2+ influx. Neurotoxicology 2012, 33, 59-69.

549

(28) McElnea, E.; Quill, B.; Docherty, N.; Irnaten, M.; Siah, W.; Clark, A.; O’Brien, C.; Wallace, D.,

550

Oxidative stress, mitochondrial dysfunction and calcium overload in human lamina cribrosa cells from

mystus)

and

protein

hydrolysate

Mitochondria:

Two

and

its

Prominent

Maillard

Players

reaction

in


the

product

Oxidative

on

combating

Stress-Induced


551

glaucoma donors. Mol. Vis. 2011, 17, 1182-1191.

552

(29) Mattson, M. P.; Lovell, M. A.; Furukawa, K.; Markesbery, W. R., Neurotrophic factors attenuate

553

glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and

554

neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J. Neurochem. 1995,

555

65, 1740-1751.

556

(30) Khora, S. S., Marine fish-derived bioactive peptides and proteins for human therapeutics. Int. J.

557

Pharm. Pharm. Sc. 2013, 5, 31-37.

558

(31) Lu, J.; Hou, H.; Fan, Y.; Yang, T.; Li, B., Identification of MMP-1 inhibitory peptides from cod

559

skin gelatin hydrolysates and the inhibition mechanism by MAPK signaling pathway. J. Funct. Foods

560

2017, 33, 251-260.

561

(32) Olatunji, O. J.; Feng, Y.; Olatunji, O. O.; Tang, J.; Wei, Y.; Ouyang, Z.; Su, Z., Polysaccharides

562

purified from Cordyceps cicadae protects PC12 cells against glutamate-induced oxidative damage.

563

Carbohyd. Polym. 2016, 153, 187-195.

564

(33) Wang, X.; Miao, J.; Yan, C.; Ge, R.; Liang, T.; Liu, E.; Li, Q., Chitosan attenuates

565

dibutyltin-induced apoptosis in PC12 cells through inhibition of the mitochondria-dependent pathway.

566

Carbohyd. Polym. 2016, 151, 996-1005.

567

(34) Boshra, V.; Atwa, A., Effect of cerebrolysin on oxidative stress-induced apoptosis in an

568

experimental rat model of myocardial ischemia. Physiol. Int. 2016, 103, 310-320.

569

(35) Ott, M.; Gogvadze, V.; Orrenius, S.; Zhivotovsky, B., Mitochondria, oxidative stress and cell death.

570

Apoptosis 2007, 12, 913-922.

571

(36) Tang, X. Q.; Ren, Y. K.; Zhou, C. F.; Yang, C. T.; Gu, H. F.; He, J. Q.; Chen, R. Q.; Zhuang, Y. Y.;

572

Fang, H. R.; Wang, C. Y., Hydrogen sulfide prevents formaldehyde-induced neurotoxicity to PC12 cells

573

by attenuation of mitochondrial dysfunction and pro-apoptotic potential. Neurochem. Int. 2012, 61,

574

16-24.

575

(37) Liu, J.; Chen, Z.; He, J.; Zhang, Y.; Zhang, T.; Jiang, Y., Anti-oxidative and Anti-apoptosis Effects

576

of Egg White Peptide, Trp-Asn-Trp-Ala-Asp, against H2O2-induced Oxidative Stress in Human

577

Embryonic Kidney 293 Cells. Food Funct. 2014, 5, 3179-3188.

578

(38) Zheng, L.; Zhao, Y.; Dong, H.; Su, G.; Zhao, M., Structure-activity relationship of antioxidant

579

dipeptides: Dominant role of Tyr, Trp, Cys and Met residues. J. Func. Foods 2016, 21, 485-496.

580

(39) Pihlanto, A., Antioxidative peptides derived from milk proteins. Int. Dairy J. 2006, 16, 1306-1314.


Page 24 of 34

Page 25 of 34


581

(40) Crompton, M., The mitochondrial permeability transition pore and its role in cell death. Apoptosis

582

2007, 12, 815-833.

583

(41) Sousa, S. C.; Maciel, E. N.; Vercesi, A. E.; Castilho, R. F., Ca2+-induced oxidative stress in brain

584

mitochondria treated with the respiratory chain inhibitor rotenone. Febs Lett. 2003, 543, 179-183.

585

(42) Petit, P. X.; Susin, S. A.; Zamzami, N.; Mignotte, B.; Kroemer, G., Mitochondria and programmed

586

cell death: back to the future. Febs Lett. 1996, 396, 7-13.

587

(43) Kim, E. J.; Jung, I. H.; Van Le, T. K.; Jeong, J. J.; Kim, N. J.; Kim, D. H., Ginsenosides Rg5 and

588

Rh3 protect scopolamine-induced memory deficits in mice. J. Ethnopharmacol. 2013, 146, 294-299.

589

(44) Braughler, J. M.; Hall, E. D., Central nervous system trauma and stroke. I. Biochemical

590

considerations for oxygen radical formation and lipid peroxidation. Free Radical Bio. Med. 1989, 6,

591

289-301.

592

(45) Chen, H. S.; Pellegrini, J. W.; Aggarwal, S. K.; Lei, S. Z.; Warach, S.; Jensen, F. E.; Lipton, S. A.,

593

Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage

594

against NMDA receptor-mediated neurotoxicity. J. Neurosci. 1992, 12, 4427-4436.

595

(46) Lipton, S. A.; Choi, Y. B.; Pan, Z. H.; Lei, S. Z.; Chen, H. S. V.; Sucher, N. J.; Loscalzo, J.; Singel,

596

D. J.; Stamler, J. S., A redox-based mechanism for the neuroprotective and neurodestructive effects of

597

nitric oxide and related nitroso-compounds. Nature 1993, 364, 626-632.

598

(47) Gross, A.; McDonnell, J. M.; Korsmeyer, S. J., BCL-2 family members and the mitochondria in

599

apoptosis. Gene. Dev. 1999, 13, 1899-1911.

600

(48) Cory, S.; Adams, J. M., The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev.

601

Cancer 2002, 2, 647-656.

602



603

Figure captions:

604

Fig. 1 (A) Chromatography of APH separated by gel filtration on a Sephadex G-25 column (at 220

605

nm). (B) AChE inhibitory activity of each fraction；(C) RP-HPLC purification chromatography of

606

Fr.4; (D) AChE inhibitory activity of each subfraction (Fr.4-1~10); (E) Mass spectrum of

607

Pro-Ala-Tyr-Cys-Ser (PAYCS, m/z 540.1936 Da); (F) Mass spectrum of Cys-Val-Gly-Ser-Tyr

608

(CVGSY, m/z 527.1955 Da); (G) AChE inhibitory capacities of PAYCS and CVGSY; The sample

609

concentration for AChE inhibitory capacity detection was 10 mg/mL. Superscript letters (a, b, c)

610

represent the statistical significances between samples, p < 0.05.

611

Fig. 2 Effects of PAYCS and CVGSY on glutamate-induced oxidative stress in PC12 cells. (A)

612

Cell viability after treatment with PAYCS and CVGSY (0.5 mg/mL); (B) Cell viability after

613

treatment with PAYCS and CVGSY (0.5 mg/mL) and 32.5 mM glutamate for 24 h; (C) LDH

614

leakage in PC12 cells. △: vs. control group, p < 0.05. *: vs. glutamate group, p < 0.05. #

615

represents the significant differences among sample groups, p < 0.05.

616

Fig. 3 Morphological analysis of nuclear chromatins in PC-12 cells as determined by Hoechst

617

33258 staining (100×).

618

Fig. 4 Effects of PAYCS and CVGSY (0.5 mg/mL) on the glutamate-induced (A) intracellular

619

ROS accumulation; (B) SOD activity down-regulation; (C) GSH-px activity down-regulation; (D)

620

MDA levels overproduction. △: vs. control group, p < 0.05. *: vs. glutamate group, p < 0.05. #

621

represents the significant differences among sample groups, p < 0.05.

622

Fig. 5 Effects of PAYCS and CVGSY (0.5 mg/mL) on the glutamate-induced intracellular Ca2+

623

influx (A) and MMP loss (B). [Ca2+]i was detected with a fluorescence spectrophotometer. PAYCS

624

and CVGSY (0.5 mg/mL) could inhibit the [Ca2+]i increment. JC-1 mmonomer and aggregates

625

were measured by fluorescence spectrophotometer. The ratio of aggregates intensity and monomer

626

intensity of JC-1 could be used to represent the change of MMP. △: vs. control group, p < 0.05. *:

627

vs. glutamate group, p < 0.05. # represents the significant differences among sample groups, p

Neuroprotective effects of acetylcholinesterase inhibitory peptides

Recommend Documents